Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-72125-0
Affiliations:
7
Authors:
18
Go to article
Institutions Authors Share
Princess Margaret Cancer Centre, U of T, Canada
12.000000
12.000000
 0.67
University of Toronto (U of T), Canada
2.000000
 0.11
Hospital Universitario 12 de Octubre, Spain
2.000000
 0.11
Oncology Institute of Southern Switzerland (IOSI), Switzerland
1.000000
 0.06
Health Sciences North, Canada
1.000000
 0.06
Interested in Oncology and Carcinogenesis?